Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

NCT07706933 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

456

Enrollment

OTHER_GOV

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dalpiciclib
DRUG: Abemaciclib/Ribociclib

Sponsor

Henan Cancer Hospital